ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
60,884.12
0.95%
S&P 500
5,460.48
-0.41%
Dow Jones
39,118.86
-0.12%
US Dollar vs Yen
160.8775
0.00%
Brent Oil
84.85
0.00%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Vicuron Pharmaceuticals (MM) (MICU)

  7. Vicuron Pharmaceuticals (MM) (MICU) ニュース

MICU

Vicuron (MICU)

Vicuron Pharmaceuticals (MM)
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:MICU
日付受信時刻ニュースソース見出しコード企業名
2005/09/1417 : 00PR Newswire (US)Pfizer Completes Acquisition of Vicuron PharmaceuticalsNASDAQ:MICU
2005/09/1202 : 00PR Newswire (US)Vicuron Pharmaceuticals - Announces Expiration of Hart-Scott-Rodino Act Waiting Period and Expected Closing Date for AcquisitionNASDAQ:MICU
2005/08/1906 : 30PR Newswire (US)Vicuron Pharmaceuticals Files New Drug Application (NDA) for Anidulafungin for Treatment of Invasive Candidiasis/CandidemiaNASDAQ:MICU
2005/08/1606 : 30PR Newswire (US)Vicuron Pharmaceuticals Stockholders Approve Merger With PfizerNASDAQ:MICU
2005/08/0506 : 30PR Newswire (US)Vicuron Pharmaceuticals Announces Second Quarter 2005 Financial ResultsNASDAQ:MICUVicuron Pharmaceuticals (MM)
2005/06/1615 : 00PR Newswire (US)Pfizer to Acquire Vicuron Pharmaceuticals to Extend its Research Commitment in Anti-InfectivesNASDAQ:MICUVicuron Pharmaceuticals (MM)
2005/06/0216 : 00PR Newswire (US)Vicuron Pharmaceuticals Receives Issued Patent for Dalbavancin Dosing by U.S. Patent and Trademark OfficeNASDAQ:MICU
2005/05/3116 : 00PR Newswire (US)Vicuron Pharmaceuticals Files Amendment to Anidulafungin New Drug Application (NDA) for Treatment of Esophageal CandidiasisNASDAQ:MICU
2005/05/2706 : 30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Friedman Billings Ramsey 9th Annual Growth Investor Conference and the Pacific GrowthNASDAQ:MICU
2005/05/1806 : 30PR Newswire (US)Vicuron Pharmaceuticals to Present at the 2005 Needham Biotech ConferenceNASDAQ:MICU
2005/05/1116 : 00PR Newswire (US)Vicuron Pharmaceuticals Announces Extension of FDA Review of Dalbavancin New Drug ApplicationNASDAQ:MICU
2005/05/1006 : 30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Bear Stearns 2005 Healthcare Conference and the Banc of America Securities HealthcareNASDAQ:MICU
2005/05/0606 : 30PR Newswire (US)Vicuron Pharmaceuticals Announces First Quarter 2005 Financial ResultsNASDAQ:MICU
2005/04/2821 : 30PR Newswire (US)Vicuron Pharmaceuticals to Present at Morgan Stanley Healthcare Unplugged ConferenceNASDAQ:MICU
2005/03/3107 : 30PR Newswire (US)Vicuron Pharmaceuticals Extends Pfizer Deal to Develop Oral Antibiotics for Community MarketNASDAQ:MICU
2005/03/1106 : 30PR Newswire (US)Vicuron Pharmaceuticals Announces Fourth Quarter 2004 Financial ResultsNASDAQ:MICU
2005/03/1021 : 30PR Newswire (US)Vicuron Pharmaceuticals to Present at the SG Cowen & Co. 25th Annual Health Care ConferenceNASDAQ:MICU
2005/03/0416 : 00PR Newswire (US)Vicuron Pharmaceuticals Provides Update on Novartis Peptide Deformylase Inhibitor ProgramNASDAQ:MICU
2005/02/2521 : 30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Wells Fargo Securities Healthcare ConferenceNASDAQ:MICU
2005/02/2416 : 00PR Newswire (US)Vicuron Pharmaceuticals Granted Priority Review of Dalbavancin NDA by FDA in Complicated Skin and Soft Tissue InfectionsNASDAQ:MICU
2005/02/1721 : 30PR Newswire (US)Vicuron Pharmaceuticals to Present at the BIO CEO & Investor Conference 2005NASDAQ:MICU
2005/02/0716 : 00PR Newswire (US)Vicuron Pharmaceuticals Announces Phase 3 Trial Results Demonstrate Superiority of Anidulafungin Versus Fluconazole in InvasiveNASDAQ:MICU
2005/01/2416 : 00PR Newswire (US)Vicuron Pharmaceuticals Promotes David S. Krause, M.D., to Executive Vice President and Chief Medical OfficerNASDAQ:MICU
2005/01/0521 : 30PR Newswire (US)Vicuron Pharmaceuticals to Present at the 23rd Annual JP Morgan Healthcare ConferenceNASDAQ:MICU
2004/12/2206 : 30PR Newswire (US)Vicuron Pharmaceuticals Submits New Drug Application for Dalbavancin to U.S. Food and Drug AdministrationNASDAQ:MICU
2004/11/2921 : 30PR Newswire (US)Vicuron Pharmaceuticals to Present at the Lazard Freres & Co. Healthcare ConferenceNASDAQ:MICU
2004/11/0506 : 30PR Newswire (US)Vicuron Pharmaceuticals Announces Third Quarter 2004 Financial ResultsNASDAQ:MICU
2004/11/0116 : 00PR Newswire (US)Vicuron Pharmaceuticals Announces Data at ICAAC Supporting Next-Generation Lincosamide ProgramNASDAQ:MICU
2004/11/0116 : 00PR Newswire (US)Vicuron Pharmaceuticals Announces Data at ICAAC Demonstrating Potency of Anidulafungin and DalbavancinNASDAQ:MICU
2004/10/2521 : 30PR Newswire (US)Vicuron Pharmaceuticals Announces 40 Presentations at ICAAC Highlighting Pipeline and Late-Stage ProductsNASDAQ:MICU
 Showing the most relevant articles for your search:NASDAQ:MICU

最近閲覧した銘柄

BIT
P1EHU6
BNP Paribas Issuance
BIT
UR9ZNV
UniCredit Bank
BOV
G2DI33M
G2D Investments
BIT
P21XL8
NLBNPIT21XL8 20351221 14...
BIT
P1Q6M5
BNP Paribas Issuance
TSXV
FCLI
Full Circle Lithium
HITB
SHIPETH
ShipChain
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有